GLP-1 expression decreases significantly in PCOS subjects contributing to increased insulin resistance

Brown Adipose Tissue is reduced in PCOS subjects due to low UCP-1 levels leading to increased Visceral adiposity

Testosterone is increased in PCOS subjects as compared to control causing hyperandrogenism

Byzepta^TM treatment achieves significant increase in GLP-1 and UCP-1 levels, resulting in decreased LH and testosterone levels, improving insulin sensitivity, decreasing visceral adiposity and leading to improved clinical outcomes.

• No serious adverse effect reported

Dosage

Lean PCOS (<25 BMI) - 1 Tab OD

(To be taken 30 minutes prior breakfast)

Obese PCOS (>25 BMI) - 1 Tab BID

(To be taken 30 minutes prior breakfast & dinner)

Duration of Treatment

3 to 6 months

Disclaimer: Above data / claim is based on the clinical evidence obtained from GLP-1 RA, UCP-1 and individual API molecules, Individual Results may vary*